Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 27Prostatic Neoplasms 22Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Neoplasms 10Lung Neoplasms 10Urinary Bladder Neoplasms 8Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 7Carcinoma, Squamous Cell 6Non-Muscle Invasive Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Carcinoma, Transitional Cell 5Adenocarcinoma 5Oropharyngeal Neoplasms 4Sarcoma 3Prostatic Neoplasms, Castration-Resistant 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3HER2-positive Breast Cancer 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Vaccinia 2Recurrence 2Peritoneal Neoplasms 2Metastatic Castration-Resistant Prostate Cancer 2

Interventions

Specimen Handling 2nedaplatin 1X-Rays 1Relaxation Therapy 1Protons 1Proton Therapy 1Platinum Compounds 1Physical Therapy Modalities 1Pemetrexed 1Paclitaxel 1Docetaxel 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Resectable Lung Non-Small Cell Carcinoma × Docetaxel × Clear all
NCT06775275 2025-01-15

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
60 enrolled

Resectable Lung Non-Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡